The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

Launched by NATIONAL CHENG-KUNG UNIVERSITY HOSPITAL · Aug 21, 2020

Keywords

ClinConnect Summary

Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for H. pylori eradication, replacing clarithromycin-based triple therapy. It is because the eradication rates of triple therapy in adults and clarithromycin-contained sequential therapy in children have declined due to increasing clarithromycin resistance in both adults and children. The best regimen for H. pylori eradication should be the one which succeeds on the first attempt. However, the effectiveness and the optimal duration of bismuth-based quadruple therapy for first-line H. pylori eradi...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are \> 18 years
• • Receive gastroscopy because of dyspepsia, acid regurgitation, melena, hematemesis, or others
• Exclusion Criteria:
• • Bleeding diathesis,
• • Major organic diseases
• • Malignancy
• • Diseases treated with chemotherapy within one month
• • Diseases treated with steroids within one month
• • Diseases treated with antibiotics within one month,
• • Users of aspirin within four weeks before enrollment
• • Users of nonsteroidal anti-inflammatory drugs within four weeks before enrollment
• • Users of cyclooxygenase-2 selective inhibitors within four weeks before enrollment
• • History of H. pylori eradication
• • Ingest probiotics or probiotics-containing yogurt with a frequency of \>= twice per week one month prior to enrollment